Due to the low frequency, little is known about the molecular biology of BRAF/EGFR co-mutations or the prognosis of EGFR TKIs monotherapy and EGFR plus BRAF inhibitors in BRAF/EGFR co-mutated NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.